Form 4: Tandem Diabetes Care Director Equity Transaction

Director Myoungil Cha acquired 8,759 shares of Tandem Diabetes Care common stock through the vesting of restricted stock units.

Summary

• Director Myoungil Cha was granted 10,220 restricted stock units (RSUs) on May 20, 2026.
• Director Myoungil Cha acquired 8,759 shares of common stock on May 21, 2026, following the vesting of previously granted RSUs.
• The total beneficial ownership for the director following these transactions is 22,458 shares of common stock.
• The transactions were executed under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director equity compensation and vesting.

Positives

• Director maintains a direct equity stake of 22,458 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Future vesting of RSUs is subject to the terms of the 2023 Long-Term Incentive Plan.

Future Outlook

The 10,220 RSUs granted on May 20, 2026, are scheduled to vest on the one-year anniversary of the grant date, subject to the 2023 Plan.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard corporate governance practice in the medical device sector, reflecting typical long-term incentive compensation structures.

Comparison to Industry Standards

• The use of RSUs as a primary component of director compensation is consistent with industry standards for mid-cap medical technology companies.
• The vesting schedule of one year is common practice for non-employee director equity grants.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation vesting.

Next Steps

• Vesting of the 10,220 RSUs granted on May 20, 2026, expected on May 20, 2027.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Trading, Equity Compensation, Director Ownership